Skip to main content
Clinical Trials/NCT05015660
NCT05015660
Recruiting
N/A

LEFT Bundle Pacing vs Standard Right Ventricular Pacing for Heart Failure

McGill University Health Centre/Research Institute of the McGill University Health Centre1 site in 1 country1,300 target enrollmentSeptember 1, 2022

Overview

Phase
N/A
Intervention
Left bundle branch pacing lead
Conditions
Pacemaker DDD
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Enrollment
1300
Locations
1
Primary Endpoint
Time to first heart failure event
Status
Recruiting
Last Updated
last month

Overview

Brief Summary

High burden right ventricular (RV) pacing has been shown to increase cardiovascular mortality, incidence of heart failure (HF), worsen left ventricular (LV) function and accelerate the development of atrial fibrillation (AF). High percentage ventricular pacing and wider paced QRS in the setting of normal baseline LV ejection fractions have consistently been shown to be independent risk factors for pacing-induced cardiomyopathy. Left bundle branch pacing (LBBP) has emerged as a potential alternative pacing mechanism that may avoid LV dyssynchrony and pacing-induced LV dysfunction by mimicking native electrical conduction.

Detailed Description

We hypothesize that in patients with high degree AV block with anticipated ventricular pacing \>90%, and an EF \>35% patients undergoing LBBP will demonstrate a significantly lower number of the primary composite endpoint of cardiovascular death, heart failure events, and change in LVESVi as compared to standard RV pacing. Echos will be performed at baseline, 12, 24, and 36 months. NTproBNPs are performed at baseline and follow-up. There will be a core echo lab, and blinded adjudication of ECGs and events.

Registry
clinicaltrials.gov
Start Date
September 1, 2022
End Date
January 1, 2030
Last Updated
last month
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Responsible Party
Principal Investigator
Principal Investigator

Jacqueline Joza

Cardiac electrophysiologist

McGill University Health Centre/Research Institute of the McGill University Health Centre

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years
  • Patients with an ejection fraction of \>35%
  • Patients with an indication for ventricular pacing and high-degree atrioventricular block where the degree of anticipated RV pacing is \>90% including:
  • Third degree AV block
  • Symptomatic or asymptomatic second-degree AV block
  • First degree AV block ≥ 280ms with a narrow QRS, or ≥ 240ms with an intraventricular delay (QRS duration ≥120ms)
  • Echocardiogram within the last 3 months, with ability to have DICOM images

Exclusion Criteria

  • Indication for an implantable cardioverter defibrillator
  • Presence of a mechanical tricuspid valve
  • Any prior attempt at implantation of an ICD, CRT, HBP, or LBBP
  • Lack of capacity to consent
  • Other serious medical condition with life expectancy of \<2 years
  • Patients in whom the conduction system abnormality is expected to be transient or recover over time
  • Patients with permanent atrial fibrillation

Arms & Interventions

left bundle branch pacing

Intervention: Left bundle branch pacing lead

Right ventricular pacing

Intervention: Right ventricular active fixation lead

Outcomes

Primary Outcomes

Time to first heart failure event

Time Frame: 36 months

Defined as: (i) Emergency department (ED) visits or hospitalization for HF (requiring signs and symptoms consistent with congestive heart failure (CHF) that is responsive to oral or parenteral medications); (ii) intensification of therapy (intravenous diuretic therapy on an outpatient basis); or (iii) indication for device upgrade to CRT due to deteriorating LV function defined as an absolute decline in LVEF ≥ 10% from baseline and an LVEF ≤ 40%

Time to cardiovascular death

Time Frame: 36 months

Clinical

Worsening LV end systolic volume index by 2 years

Time Frame: 24 months

Defined as a 15% increase from baseline each year up to the two-year echo

Secondary Outcomes

  • Cardiovascular mortality(24 months)
  • Atrial fibrillation progression(24 months)
  • Change in NTproBNP level(24 months)
  • Development of new tricuspid regurgitation(24 months)
  • Change in Lead parameter(24 months)
  • New visit for Heart Failure(24 months)
  • Presence of Mitral regurgitation(24 months)
  • Quality of Life Improvement(Evaluated at 1, 12, and 24 months, measure as compared to baseline)
  • Total mortality(24 months)
  • Change in left ventricular ejection fraction(24 months)
  • Safety of procedure and long-term safety(24 months)

Study Sites (1)

Loading locations...

Similar Trials